ClinicalTrials.govrestricted
Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas
ClinicalTrials.gov study NCT04476966. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
ShareScore
32/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 12
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 8